Physician
G Athansi Orfanos MD PA
G Athansi Orfanos MD PA was paid $6.35M by Medicaid between Jan 2018 and Dec 2024, across 76 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 35% of everything it billed.
33Billing provider infoG ATHANSI ORFANOS MD PA
EDINBURG, TX 78539
EDINBURG, TX 78539
33aNPI1245453901assigned 04/11/2007
33bProvider typePediatrics Physician
28Total paid$6.35M
24GClaims284,267
24DCodes billed76
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#61 of 1,136
Median peer was paid$329K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 597 | $20K | |
| 2019 | 1,321 | $43K | |
| 2020 | 11,021 | $227K | |
| 2021 | 58,822 | $1.21M | |
| 2022 | 66,173 | $1.56M | |
| 2023 | 72,431 | $1.67M | |
| 2024incomplete | 73,902 | $1.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 35% | 60,313 | 43,782 | $2.22M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 13% | 11,041 | 10,251 | $803K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 10% | 16,878 | 15,399 | $662K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 6.0% | 28,298 | 13,137 | $380K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.4% | 4,617 | 4,466 | $345K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.3% | 4,265 | 4,161 | $337K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 4.7% | 22,300 | 20,285 | $298K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.9% | 2,857 | 2,809 | $249K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.7% | 3,174 | 3,071 | $233K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 3.1% | 18,541 | 7,505 | $199K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 1,270 | 1,233 | $93K |
| 99429 | 1.0% | 2,165 | 2,128 | $67K |
64 more codes
| 87634 | <1% | 1,114 | $54K | |
| 99382 | <1% | 582 | $52K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,706 | $45K |
| 99381 | <1% | 559 | $44K | |
| 87807 | <1% | 4,006 | $42K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,388 | $40K |
| 99051 | <1% | 6,606 | $31K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 332 | $27K |
| 92558 | <1% | 4,211 | $24K | |
| 90461 | <1% | 5,213 | $22K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,706 | $22K |
| 99383 | <1% | 148 | $12K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 185 | $9K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 124 | $8K |
| 83655 | <1% | 613 | $6K | |
| 97169 | <1% | 298 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,367 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 92 | $3K |
| 81002 | <1% | 1,136 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 92 | $2K |
| 84030 | <1% | 507 | $2K | |
| 86318 | <1% | 139 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 100 | $1K |
| 80053 | Comprehensive metabolic panel | <1% | 160 | $1K |
| 90620 | <1% | 417 | $648.47 | |
| 86580 | <1% | 89 | $638.74 | |
| 92587 | <1% | 44 | $561.84 | |
| 90651 | <1% | 581 | $561.58 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 45 | $508.50 |
| 96160 | <1% | 450 | $456.50 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 362 | $403.50 |
| 85018 | <1% | 347 | $322.38 | |
| 97802 | <1% | 2,593 | $200.06 | |
| 90619 | <1% | 448 | $159.61 | |
| 90686 | <1% | 1,374 | $127.31 | |
| 90715 | <1% | 337 | $102.88 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 776 | $43.56 |
| 99174 | <1% | 4,511 | $17.50 | |
| 96161 | <1% | 65 | $9.00 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 9,004 | $5.25 |
| 90677 | <1% | 705 | $1.53 | |
| 90688 | <1% | 68 | $0.04 | |
| 90734 | <1% | 402 | $0.01 | |
| 90647 | 0% | 2,588 | $0.00 | |
| 90723 | 0% | 2,007 | $0.00 | |
| 4140F | 0% | 16 | $0.00 | |
| 90696 | 0% | 350 | $0.00 | |
| 90680 | 0% | 1,960 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 6,396 | $0.00 |
| 3120F | 0% | 21,983 | $0.00 | |
| 90716 | 0% | 408 | $0.00 | |
| G8418 | Bmi is documented below normal parameters and a follow-up plan is documented | 0% | 125 | $0.00 |
| G0010 | Administration of hepatitis b vaccine | 0% | 686 | $0.00 |
| 36416 | 0% | 59 | $0.00 | |
| 3330F | 0% | 49 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 70 | $0.00 |
| 90710 | 0% | 519 | $0.00 | |
| 90707 | 0% | 371 | $0.00 | |
| 90633 | 0% | 1,368 | $0.00 | |
| 90670 | 0% | 2,014 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 2,852 | $0.00 |
| 99173 | 0% | 52 | $0.00 | |
| 90700 | 0% | 465 | $0.00 | |
| 90649 | 0% | 208 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialORFANOS, GERARDO (OWNER)
| Provider | Location | Paid |
|---|---|---|
| G Athanasi Orfanos DDS PLLC | Edinburg, TX | $259K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.